Metraipolis › archive › dc_628e87f1787a

Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center — Europe PMC PMID:41800034

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41800034
DOI: 10.3389/fonc.2026.1732304
License (as archived): solo-consultazione
Archived: 2026-11-05T15:01:56.515Z
SHA-256 of the archived text: 79aca6e45805ab0075eb4acbb22664a6fccdccbc34eb4ab825fdfba67dcbe6ca
Stable URL of this page: https://metraipolis.com/documento/dc_628e87f1787a

How to cite

Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center — Europe PMC PMID:41800034 — Europe PMC (en), https://europepmc.org/article/MED/41800034 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_628e87f1787a (Metraipolis archive dc_628e87f1787a, sha256 79aca6e45805ab0075eb4acbb22664a6fccdccbc34eb4ab825fdfba67dcbe6ca)

BibTeX

@misc{dc628e87f1787a,
  title = {Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center — Europe PMC PMID:41800034},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41800034},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_628e87f1787a; sha256 79aca6e45805ab0075eb4acbb22664a6fccdccbc34eb4ab825fdfba67dcbe6ca},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41800034. Agents can read the archived copy with the MCP tool read_document.